drugset
drugset / Trial / NCT06710821

Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors

NCT06710821 ↗

Phase 1 Not yet recruiting 40 enrolled Yizhuo Zhang
NaSingle-groupOpen-labelTreatment

Summary

A prospective, single-center Ia/Ib clinical study divided into two parts, including Phase Ia Dose Exploration and Phase Phase Ib Extension Phase.

Timeline

Start
2024-12-01
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 40 mg/m2 Intravenous
Subject Irinotecan Small molecule 50 mg/m2 Intravenous
Subject Irinotecan Small molecule 65 mg/m2 Intravenous
Subject Irinotecan Small molecule 80 mg/m2 Intravenous
Subject Irinotecan Small molecule 100 mg/m2 Intravenous
Subject Temozolomide Small molecule 150 mg/m2 Intravenous
Subject Vincristine Small molecule 1.5 mg/m2 Intravenous

Indications

No indication recorded.